IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML) (AML)
A Phase I Study of Intravenous Plerixafor in Combination With Mitoxantrone Etoposide and Cytarabine for Relapsed or Refractory Acute Myeloid Leukemia
Sponsor: Washington University School of Medicine
Terminated
Withdrawal of support from sponsor
Other terminated trials from Washington University School of Medicine
- Gynecologic Cancer · Phase NA · Oct 2025
- Extensive-stage Small Cell Lung Cancer · Phase PHASE2 · Aug 2025
- Schizophrenia · Phase PHASE1 · Jan 2025
- Systemic Lidocaine Improves Pain Control After Surgery by Attenuating the Systemic Inflammatory Response to Surgery · Phase PHASE4 · Dec 2024
- Recurrent Rectal Cancer · Phase NA · Nov 2024
See all terminations from Washington University School of Medicine
Other Leukemia, Myeloid, Acute trials with similar outcome
This PHASE1 trial investigates Leukemia, Myeloid, Acute and is currently terminated or withdrawn. Washington University School of Medicine leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
May 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .